Holen Sie sich die Stockscreener-App
22.86
3.35%
0.74
Schlusskurs vom Vortag:
$22.12
Offen:
$22.07
24-Stunden-Volumen:
100.85K
Relative Volume:
0.97
Marktkapitalisierung:
$330.92M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.1926
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
-0.44%
1M Leistung:
+53.11%
6M Leistung:
+68.09%
1J Leistung:
+69.46%
1-Tages-Spanne:
$21.00
$23.32
1-Wochen-Bereich:
$21.00
$24.75
52-Wochen-Spanne:
$10.80
$24.75
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
22.86 | 332.37M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
What analysts say about Inhibrx Biosciences Inc. stockExceptional gains - Autocar Professional
T.T. Limited (TTL) vs yyyExceptional earning trajectories - jammulinksnews.com
What analysts say about Appian Corporation stockRecord-setting profit potential - jammulinksnews.com
Top Quality Stocks Trusted Financial InsightsSuperior risk-adjusted returns - jammulinksnews.com
Is CAPL a good long term investmentOutstanding capital appreciation - jammulinksnews.com
Is Inhibrx Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
What drives Inhibrx Biosciences Inc. stock priceRapid return acceleration - jammulinksnews.com
How Technology Stocks Are Reshaping India’s Market Insider Stock RecommendationsTremendous return rates - Autocar Professional
Inhibrx Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Top Stocks for Hedge Fund Investments Elite Trader Market TipsBreakthrough profit margins - printweek.in
Best Stocks for Aggressive Investors in India High Value Stock PicksBreakthrough profits - Autocar Professional
why ivda stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
What drives SERV stock priceHigh-performance investment picks - jammulinksnews.com
What drives PLAB stock priceExceptional stock performance - jammulinksnews.com
Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype - Seeking Alpha
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionHigh Return Setup Scanner - beatles.ru
What makes Inhibrx Biosciences Inc. stock price move sharplyROI Driven Alerts - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
(INBX) Trading Signals - news.stocktradersdaily.com
Why INBX Is A Stock To Watch In 2025 - RTTNews
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Growth Index - MarketScreener
How To Trade (INBX) - news.stocktradersdaily.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Defensive Index - MarketScreener
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting - TipRanks
Inhibrx Reports First Quarter 2025 Financial Results - BioSpace
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - biocentury.com
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):